Daraxonrasib, a first in class RAS(ON) inhibitor, has more than doubled overall survival versus chemotherapy in previously treated metastatic pancreatic cancer in the pivotal phase 3 RASolute 302 trial—early data that could reshape second line care once fully validated and reviewed.